U.S. Senate Republican Leader Mitch McConnell applauded the move. “Given the public health epidemic of prescription drug abuse and the ravaging effects it has on families all across Kentucky, this announcement is great news and will prevent an influx of crushable, generic OxyContin from coming to market,” McConnell said in a release.
OxyContin is a potent drug designed to treat severe pain. Without abuse-deterrent formulas, addicts can crush the pills to get an immediate heroin-like high. The reformulated product has properties that make the tablet harder to crush, break, or dissolve and that prevent it from being injected in order to achieve a quick high, an FDA press release said.
Drug overdoses are now the
leading cause of death in Kentucky, and law enforcement, lawmakers and health providers have expressed their concerns that crushable, generic versions would worsen the problem.
The FDA decision came on the same day manufacturer Purdue Pharma’s
patent on the original drug was set to
expire, and McConnell has been actively meeting with federal officials
on behalf of those concerned. Rep. Hal Rogers, R-5th, also lobbied for it. (Read more)
In an editorial, the Lexington Herald-Leader points out that the move means a continued OxyContin monopoly and more profits for Purdue Pharma, which “paid $600 million in fines in 2007, and three of the company’s
executives paid a total of $34.5 million, after they pleaded guilty to
misleading doctors and the public about OxyContin’s addictiveness. . . . We wonder why Rogers and McConnell aren’t calling for Purdue to voluntarily share its new formulation.”